Cytokinetics - CYTK Stock Forecast, Price & News

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Analyst Ratings Changes

CYTK has been the topic of several research reports. Needham & Company LLC increased their price target on shares of Cytokinetics from $52.00 to $60.00 in a research report on Thursday, May 5th. HC Wainwright reaffirmed a "buy" rating and issued a $75.00 price objective on shares of Cytokinetics in a research note on Tuesday, May 24th. StockNews.com upgraded Cytokinetics from a "sell" rating to a "hold" rating in a report on Monday, August 8th. Mizuho lifted their price objective on Cytokinetics from $54.00 to $80.00 and gave the company a "buy" rating in a report on Monday, May 16th. Finally, Piper Sandler upped their target price on shares of Cytokinetics from $50.00 to $72.00 and gave the company an "overweight" rating in a research note on Thursday, June 9th. One equities research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, Cytokinetics has a consensus rating of "Moderate Buy" and an average price target of $59.00.

Cytokinetics Stock Up 1.7 %

CYTK traded up $0.83 on Friday, hitting $50.30. The company had a trading volume of 850,601 shares, compared to its average volume of 1,577,336. The stock has a fifty day moving average price of $43.42 and a 200-day moving average price of $39.57. The company has a debt-to-equity ratio of 1.77, a quick ratio of 9.33 and a current ratio of 9.01. Cytokinetics has a 12-month low of $29.10 and a 12-month high of $54.74. The stock has a market capitalization of $4.74 billion, a price-to-earnings ratio of -19.42 and a beta of 1.14.

Cytokinetics (NASDAQ:CYTK - Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.81. The firm had revenue of $88.97 million during the quarter, compared to the consensus estimate of $3.73 million. Cytokinetics had a negative return on equity of 118.37% and a negative net margin of 142.85%. The firm's revenue was up 3029.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.86) EPS. Analysts predict that Cytokinetics will post -3.8 EPS for the current fiscal year.

Insider Buying and Selling at Cytokinetics

In related news, CEO Robert I. Blum sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $43.11, for a total value of $431,100.00. Following the sale, the chief executive officer now owns 409,124 shares of the company's stock, valued at $17,637,335.64. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, EVP Fady Ibraham Malik sold 21,500 shares of the business's stock in a transaction that occurred on Thursday, July 14th. The shares were sold at an average price of $43.43, for a total value of $933,745.00. Following the completion of the transaction, the executive vice president now owns 168,346 shares of the company's stock, valued at $7,311,266.78. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Robert I. Blum sold 10,000 shares of the company's stock in a transaction on Monday, May 16th. The stock was sold at an average price of $43.11, for a total value of $431,100.00. Following the sale, the chief executive officer now owns 409,124 shares of the company's stock, valued at $17,637,335.64. The disclosure for this sale can be found here. Insiders have sold a total of 71,500 shares of company stock valued at $3,038,445 over the last quarter. 5.00% of the stock is owned by company insiders.